Abrégé

The invention relates to a cell culture membrane insert (120) and to a device (110) and a method (210) for detecting at least one electrochemical variable of a cell culture (112). The cell culture (112) can be at least one of any cell type of at least one species in a mono- or co-culture, particularly preferable are cell cultures which are exposed to at least one gas or aerosol. The cell culture membrane insert (120) comprises - an open support (128) which is designed to expose a cell culture (112) to at least one gas or aerosol (114), wherein a membrane (130) which has at least one surface (132) is introduced into the support (128), said surface being designed to receive the cell culture (112), and the membrane (130) has o pores (134) for diffusing a nutrient medium (136) through the membrane (130) and o an electrode assembly (130) on the at least one surface (132) designed to receive the cell culture (112), said electrode assembly (130) comprising at least two electrodes, and - at least two contact points (146, 146'). Each contact point (146, 146') is designed to produce an electric connection between one of the electrodes and a respective electric contact (144, 144') which is not encompassed by the cell culture membrane insert (120). In particular, the method and the device (110) allow a time-resolved, non-invasive, and marking-free examination and monitoring of cell cultures (112) which can be exposed to at least one gas or aerosol (114) in particular, said examination and monitoring being as close to reality as possible.

Classes IPC  ?

• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• G01N 27/02 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 27/28 - Composants de cellules électrolytiques

Abrégé

The present invention involves methods for the ex-vivo diagnosis of prostate cancer comprising the steps of i) providing a sample from a patient suspected of having prostate cancer and ii) analysing the expression level of at least one newly identified biomarker for prostate cancer in the sample, wherein, if the expression level of said biomarker is above a threshold value, the sample is designated as prostate cancer positive. Further, the invention involves stringent sample and method quality control criteria to ensure a reliable and specific method of diagnosing prostate cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention provides polypeptides and nucleic acid molecules that are useful in identifying.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• A01K 67/033 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux Élevage ou obtention d'invertébrés; Nouvelles races d'invertébrés
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

Prostate cancer is the most prevalent solid cancer among men in Western Countries. The clinical behavior of localized prostate cancer is highly variable. Hence, there is a high clinical need for precise biomarkers for identification of aggressive disease in addition to established clinical parameters. The present invention relates to a prognostic multi-gene expression score based on transcriptome-wide gene expression analysis providing a method for calculating a score (ProstaTrend score) that allows the prediction of death of disease (DoD) and/or biochemical recurrence (BCR), long-term prognosis and outcome of prostate cancer patients. The present invention is an independent predictor of prognosis and is suitable for the identification of high-risk patients among patients with a clinical classification of low or intermediate risk prior and after surgery, such as radical prostatectomy.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
• G16B 40/20 - Analyse de données supervisée

Abrégé

A methods of implanting atoms into a substrate, wherein the atoms are at least some of the constituent atoms of a molecule and wherein the molecule comprises one or more colour centre atom(s) and one or more satellite atom(s). In come embodiments, the molecule comprises not more than three colour centre atoms of the same element of the group. In some embodiments, the molecule comprises one or more colour centre atom(s) other than N, on other embodiments, the molecule comprises at least 6 satellite atoms of N. In some embodiments, the molecule comprises one or more satellite atoms other than 13C. A method of manufacturing a quantum register comprising a colour centre and at least one nuclear spin isotope atom in a substrate, wherein the colour centre of the quantum register is a colour centre formed by a colour centre atom implanted into the substrate according to one of the above methods. A quantum register comprising such colour centre and at least one nuclear spin isotope atom in a substrate. Finally, a use of a molecule that comprises one or more colour centre atom(s) and one or more satellite atom(s) for the manufacture of a quantum register.

Classes IPC  ?

• C30B 29/04 - Diamant
• C23C 14/48 - Implantation d'ions
• B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron
• G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
• H01L 21/265 - Bombardement par des radiations ondulatoires ou corpusculaires par des radiations d'énergie élevée produisant une implantation d'ions

Abrégé

A methods of implanting atoms into a substrate, wherein the atoms are at least some of the constituent atoms of a molecule and wherein the molecule comprises one or more colour centre atom(s) and one or more satellite atom(s). In come embodiments, the molecule comprises not more than three colour centre atoms of the same element of the group. In some embodiments, the molecule comprises one or more colour centre atom(s) other than N, on other embodiments, the molecule comprises at least 6 satellite atoms of N. In some embodiments, the molecule comprises one or more satellite atoms other than 13C. A method of manufacturing a quantum register comprising a colour centre and at least one nuclear spin isotope atom in a substrate, wherein the colour centre of the quantum register is a colour centre formed by a colour centre atom implanted into the substrate according to one of the above methods. A quantum register comprising such colour centre and at least one nuclear spin isotope atom in a substrate. Finally, a use of a molecule that comprises one or more colour centre atom(s) and one or more satellite atom(s) for the manufacture of a quantum register.

Classes IPC  ?

• C30B 29/04 - Diamant
• C23C 14/48 - Implantation d'ions
• B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron
• G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
• H01L 21/265 - Bombardement par des radiations ondulatoires ou corpusculaires par des radiations d'énergie élevée produisant une implantation d'ions
• C30B 29/36 - Carbures
• C30B 31/22 - Dopage par irradiation au moyen de radiations électromagnétiques ou par rayonnement corpusculaire par implantation d'ions
• C30B 33/04 - Post-traitement des monocristaux ou des matériaux polycristallins homogènes de structure déterminée en utilisant des champs électriques ou magnétiques ou des rayonnements corpusculaires
• C30B 29/06 - Silicium

Abrégé

The invention relates to a pharmaceutical composition comprising BAY 86-5277 or salt thereof for use in the treatment and/or prevention of a medical condition associated with a viral infection and comprising hyperinflammation in a human subject. The invention further relates to a combination of BAY 86-5277 or a salt thereof and at least one other treatment, such as a guideline treatment for severe respiratory disease, for example recommended by the S3 guideline on in-patient treatment of COVID-19, preferably a glucocorticoid, more preferably dexamethasone. The invention further relates to a pharmaceutical composition comprising BAY 86-5277 or salt thereof or said combination with a glucocorticoid, and use of the combination or composition, in the treatment and/or prevention of a viral infection in a subject and/or a medical condition associated with hyperinflammation, preferably hyperinflammation in the respiratory tract, acute respiratory failure, pneumonia, acute respiratory distress syndrome and/or multiorgan failure. In preferred embodiments, the invention relates to the treatment and/or prevention of a medical condition associated with a SARS-CoV infection, preferably SARS-CoV-2 infection.

Classes IPC  ?

• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention provides a device (10) and a method for determining the penetration of a particle (42a) from a particle source (40) into a material (12), which enable simple and cost-effective, highly spatially resolved particle detection, in particular individual particle detection, allowing the penetration of particles (42a) into a material (12) to be detected quickly and reliably. In addition, deterministic particle implantation can be achieved in a simple and cost-effective manner with the present invention.

Classes IPC  ?

• G01N 27/04 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance
• H01J 37/30 - Tubes à faisceau électronique ou ionique destinés aux traitements localisés d'objets
• H01L 21/00 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de dispositifs à semi-conducteurs ou de dispositifs à l'état solide, ou bien de leurs parties constitutives
• H01L 21/66 - Test ou mesure durant la fabrication ou le traitement

Abrégé

The present invention provides polypeptides and nucleic acid molecules that are useful in identifying modulators of adhesion GPCRs or PC1/PC1-like proteins.

Classes IPC  ?

• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The invention relates to a method for detecting analytes by means of an immobilised analyte binding partner and deformable particles, as well as to a kit and to their use for the detection of toxins and pathogens, in particular metal ions, viruses or bacteria in food, animal feed, detergent, dishwashing detergent, personal care, cosmetics, pharmaceutical products, process water, soil, water, drinking water and/or waste water samples and/or body fluids.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/546 - Résine synthétique sous forme de particules pouvant être mises en suspension dans l'eau

Abrégé

The invention relates to a method, to a surface, to a particle, and to a kit for the detection of low molecular weight analytes such as crop protection agents in samples. In particular, the invention relates to a method for the detection of glyphosate through protein-functionalised surfaces and functionalised particles by means of reflection interference contrast microscopy (RICM).

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/545 - Résine synthétique
• C07K 14/37 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de champignons
• C12N 9/10 - Transférases (2.)

Abrégé

Prostate cancer is the most prevalent solid cancer among men in Western Countries. The clinical behavior of localized prostate cancer is highly variable. Hence, there is a high clinical need for precise biomarkers for identification of aggressive disease in addition to established clinical parameters. The present invention relates to a prognostic multi-gene expression score based on transcriptome-wide gene expression analysis providing a method for calculating a score (ProstaTrend score) that allows the prediction of death of disease (DoD) and/or biochemical recurrence (BCR), long-term prognosis and outcome of prostate cancer patients. The present invention is an independent predictor of prognosis and is suitable for the identification of high-risk patients among patients with a clinical classification of low or intermediate risk prior and after surgery, such as radical prostatectomy.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression

Abrégé

The invention relates to a method for the detection of hormonally active compounds by means of immobilised sulphotransferases and deformable particles, as well as to a kit and their use for the detection of hormonally active compounds in food, detergent, dishwashing detergent, personal care, cosmetic, pharmaceutical, soil, water, drinking water and/or waste water samples.

Classes IPC  ?

• C12N 9/10 - Transférases (2.)
• C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The invention relates to a device for conducting radiation, a photodetector arrangement, and a method for spatially resolved spectral analysis.

Classes IPC  ?

• G01J 3/28 - Étude du spectre
• G01N 21/31 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique
• G01J 3/12 - Production du spectreMonochromateurs

Abrégé

The invention makes available a device for applying tactile stimuli during apnoea phases in premature babies (15), having - at least one pump (30), - at least one pressure detection sensor (41), - at least one cuff (10) having at least one chamber (11, 11'), and - at least one flexible line (12, 12') which connects an output of the at least one pump (30) to the at least one cuff (10) and via which at least one chamber (11, 11') of the at least one cuff (10) can be filled with and emptied of a fluid, wherein the pressure generated at the at least one cuff (10) can be measured with the at least one pressure detection sensor (41), and - a control device, wherein the at least one pump (30) is configured for filling and emptying the at least one chamber (11, 11') of the at least one cuff (10). The invention further relates to a cuff (10) for use in the device according to the invention, and to a method for controlling the device during apnoea phases in premature babies (15).

Classes IPC  ?

• A61H 9/00 - Massages pneumatiques ou hydrauliques

Abrégé

The invention relates to a sensor system (NVMS) with a quantum dot, which can comprise a paramagnetic centre (NV1). The sensor system comprises a control and analysis device (AWV), which has a first pumped radiation source (PL1), a radiation receiver (PD1), and which irradiates the quantum dot with pumped radiation (LB) by means of the first pumped radiation source (PL1). The quantum dot emits fluorescence radiation (FL) as it is irradiated with the pumped radiation (LB), the fluorescence radiation being dependent on a physical parameter. Depending on the fluorescence radiation (FL), the control and analysis device (AWV) generates a first output signal (out) having a signal component that represents a measurement value. The measurement value is dependent on the value of the physical parameter. By means of one or more compensation coils (LC), the control and analysis device (AWV) controls the sensitivity of the quantum dot for the physical parameter in a compensatory manner, such that the receiver output signal (SO) of the radiation receiver (PD1) then no longer has any substantial component of the transmission signal (S5).

Classes IPC  ?

• G01D 5/26 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensibleMoyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminéTransducteurs non spécialement adaptés à une variable particulière utilisant des moyens optiques, c.-à-d. utilisant de la lumière infrarouge, visible ou ultraviolette
• G01D 21/00 - Mesures ou tests non prévus ailleurs
• G01D 5/14 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensibleMoyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminéTransducteurs non spécialement adaptés à une variable particulière utilisant des moyens électriques ou magnétiques influençant la valeur d'un courant ou d'une tension
• G01D 5/245 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensibleMoyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminéTransducteurs non spécialement adaptés à une variable particulière utilisant des moyens électriques ou magnétiques influençant les caractéristiques d'impulsionsMoyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensibleMoyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminéTransducteurs non spécialement adaptés à une variable particulière utilisant des moyens électriques ou magnétiques produisant des impulsions ou des trains d'impulsions utilisant un nombre variable d'impulsions dans un train
• G01R 33/032 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des dispositifs magnéto-optiques, p. ex. par effet Faraday
• G01N 24/00 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin

Abrégé

The invention consists of a process by which elastographic measurement data of various tissue types and their reference with regard to the growth properties of the respective tissue type can be predicted. From the growth properties it can be concluded that the tissue growth is aggressive and that a tumour disease may be present. This therapy-supporting procedure is independent of the data source, i.e. the range of applications extends from individual elastographically detectable cell samples to data collection by MR scanners.

Classes IPC  ?

• G06T 7/00 - Analyse d'image
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
• A61B 8/08 - Applications cliniques
• G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté

Abrégé

The present invention relates to a method for addressing qubits (14, 16), to a device (10) for addressing qubits (14, 16) and to a method for producing the device (10). The addressing of qubits (14, 16) is made possible thereby in a simple way, without the risk of crosstalk between different qubits (14, 16). The addressing can be carried out both individually and jointly for different qubits (14, 16). In addition, the qubits (14, 16) can also be easily read out.

Classes IPC  ?

• G06N 10/00 - Informatique quantique, c.-à-d. traitement de l’information fondé sur des phénomènes de mécanique quantique
• H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
• H01L 29/16 - Corps semi-conducteurs caractérisés par les matériaux dont ils sont constitués comprenant, mis à part les matériaux de dopage ou autres impuretés, seulement des éléments du groupe IV de la classification périodique, sous forme non combinée

Abrégé

The present invention provides methods for expanding mesenchymal stem cells obtained from the outer root sheath of hair follicles. The invention further provides methods for differentiating the expanded cells into differentiated cells and tissues, and cells obtainable by the methods of the invention.

Classes IPC  ?

• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux

Abrégé

The invention relates to a method for generating at least one deterministic F-centre in a diamond layer. By implanting at least one dopant in the diamond layer in a first step and incorporating at least one foreign atom in the diamond layer by means of low-energy ion bombardment for the formation of the F-centre in a second step, very high conversion rates of greater than 70% can be achieved. This is a significant increase in relation to undoped diamond, in which the conversion rates are only around 6%. Via doping with a donor, such as phosphorous, oxygen or sulphur, a very good conversion into negatively charged F-centres can be achieved, which are used for Qubit applications.

Classes IPC  ?

• C30B 29/04 - Diamant
• C30B 31/22 - Dopage par irradiation au moyen de radiations électromagnétiques ou par rayonnement corpusculaire par implantation d'ions
• C30B 33/02 - Traitement thermique
• B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron

Abrégé

The invention relates to a method and a kit for detecting analytes, particularly low-molecular analytes. According to the invention, a simple method for detecting low-molecular analytes is provided in which method the analytes to be detected act as competitors for immobilized enzymes. As a result of the inhibition, a conclusion can be drawn, on the basis of the reduced substrate metabolism, regarding the analyte concentration. In particular, the invention relates to a method for detecting glyphosate.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The invention relates to a method, a surface, a particle and a kit for the detection of low-molecular analytes, such as plant protection products, in samples. The invention particularly relates to a method for the detection of glyphosate by means of protein-functionalized surfaces and functionalized particles by way of reflection interference contrast microscopy (RICM).

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The invention relates to a device (50) for generating and controlling a magnetic field strength and to a method for generating and controlling a magnetic field strength, wherein the generation is very stable and precise. Preferably, reference values of physical variables can be generated relatively simply and economically. Also, magnetic flow densities with high resolutions and which are in particular robust, can be measured. The invention can also be used for transmitting information, in particular ultra-wide band communication. The required devices (50) can be very small, in particular miniature, and can be mobile.

Classes IPC  ?

• G05F 7/00 - Régulation des grandeurs magnétiques
• G01R 33/032 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des dispositifs magnéto-optiques, p. ex. par effet Faraday

Abrégé

The invention relates to a device for conducting radiation, a photodetector arrangement and a method for spatially resolved spectral analysis.

Classes IPC  ?

• G01J 3/02 - SpectrométrieSpectrophotométrieMonochromateursMesure de la couleur Parties constitutives
• G01J 3/28 - Étude du spectre
• G01J 3/12 - Production du spectreMonochromateurs

Abrégé

The invention relates to a device and a method for determining a wavelength of a radiation. The device comprises at least two absorption elements (12, 14) for generating photosignals, wherein the absorption elements (12, 14) are arranged one above the other in a layer structure (16), wherein an upper absorption element (12) has a vertically varying chemical composition, which is characterized by a material gradient, in order to set a wavelength-dependent absorption coefficient, and wherein a lower absorption element (14) is chemically homogeneously formed.

Classes IPC  ?

• G01J 1/42 - Photométrie, p. ex. posemètres photographiques en utilisant des détecteurs électriques de radiations
• G01J 9/00 - Mesure du déphasage des rayons lumineuxRecherche du degré de cohérenceMesure de la longueur d'onde des rayons lumineux
• G01J 9/02 - Mesure du déphasage des rayons lumineuxRecherche du degré de cohérenceMesure de la longueur d'onde des rayons lumineux par des méthodes interférométriques
• H01L 31/08 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails dans lesquels le rayonnement commande le flux de courant à travers le dispositif, p.ex. photo-résistances
• H01L 31/18 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives
• H01L 27/146 - Structures de capteurs d'images

Abrégé

The invention relates to a deformable film made of at least one inorganic nonmetallic material which has pores, at least in some areas. The porosity of the deformable film is 10% to 90%, the thickness of the deformable film is 1 µm to 100 µm, and the average pore diameter of the pores is 2 nm to 500 nm. Because of the combination of these specific parameters, a film which is both deformable and also has good mechanical stability and breaking strength is obtained. In addition, the deformable film has a higher stability with respect to high temperatures and organic solvents than plastic films. The invention further relates to a method for producing the deformable film according to the invention and to the use of the deformable film according to the invention.

Classes IPC  ?

• C03C 11/00 - Verre alvéolé
• C03C 3/089 - Compositions pour la fabrication du verre contenant de la silice avec 40 à 90% en poids de silice contenant du bore
• C03C 21/00 - Traitement du verre, autre que sous forme de fibres ou de filaments, par diffusion d'ions ou de métaux en surface
• C03B 23/037 - Finition des feuilles de verre par étirage
• C03B 27/012 - Trempe des articles de verre par traitement thermique, p. ex. pour la cristallisationTraitement thermique d'articles en verre avant la trempe par refroidissement
• C03C 10/02 - Phase cristalline sans silice et sans silicate, p. ex. spinelle, titanate de barium

Abrégé

The invention relates to a peptide comprising (i) a main chain comprising at least one L-3,4-dihydroxyphenylalanine (DOPA), (ii) at least one integrin binding peptide, and (iii) at least one heparin binding peptide. The invention further relates to a coating for metal surfaces comprising the peptide according to the invention and a coated metal surface which promotes osseointegration that can be obtained by reacting the peptide according to the invention with a metal surface.

Classes IPC  ?

• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61L 27/34 - Matériaux macromoléculaires
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 17/14 - Peptides immobilisés sur, ou dans, un support inorganique
• A61L 27/28 - Matériaux pour le revêtement de prothèses
• A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• C07K 5/087 - Tripeptides la chaîne latérale du premier amino-acide contenant des carbocycles, p. ex. Phe, Tyr
• A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
• A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61K 6/20 - Revêtements de protection pour dents naturelles ou artificielles, p. ex. scellements, revêtements colorés ou vernis
• A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents
• A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61F 2/30 - Articulations

Abrégé

11 receptor agonist - saccharide functionalised carbaborane conjugate compounds of general formula (I): X5PSX1PX6FPGX7X8X9PX10X11X12X13X2X14YYX3X15X16X17X422, in which F, G, I, L, N, P, R, S, T, Y, X1, X2, X3, X4, X5, X6, X7,X8, X9, X10, X11, X12, X13, X14, X15, X16, and X17 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment of cancer by means of boron neutron capture therapy.

Classes IPC  ?

• C07K 14/575 - Hormones
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• C07F 5/02 - Composés du bore
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire

Abrégé

The present invention covers peptidic melanocortin 1 receptor agonist –saccharide functionalised carbaborane conjugatecompoundsof general formula (I), in which R1, X1, X2, L-His, X3, L-Arg, X4, X5, r, and CbD are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment of cancer by means of boron neutron capture therapy.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire

Abrégé

The present invention covers peptidic BB2 receptor agonist –saccharide functionalised carbaborane conjugate compounds of general formula (I), in which L-Gln, L-Trp, L-Ala, L-Val, β-Ala, L-His, L-Nle, Z, n, X, m, and CbDare as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment of cancer by means of boron neutron capture therapy.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• C07F 5/02 - Composés du bore

Abrégé

The present invention relates to Novel 1,7-dicarba-closo- dodecaborane(12) (meta-carbaborane)-derived carboxylic acids suitable for peptide modification for application in boron neutron capture therapy (BNCT).

Classes IPC  ?

• C07H 5/04 - Composés contenant des radicaux saccharide dans lesquels les liaisons carbone-oxygène ont été remplacées par le même nombre de liaisons carbone-hétéro-atomes à des atomes d'halogènes, d'azote, de soufre, de sélénium ou de tellure à l'azote
• C07H 7/06 - Radicaux hétérocycliques
• C07F 5/02 - Composés du bore

Abrégé

22244-C(COOH)-NH-COO-tert2222, X CB* is Formula (II) or Formula (III) wherein * marks the position where CB* is coupled to compound of formula (I) X and Y are independently of each other -H and -G and G is natural or synthetic monosaccharide in which the hydroxygroups are protected as well as the related 10B-enriched compounds, and its pharmaceutically acceptable salts, solvates and hydrates and mixtures thereof.

Classes IPC  ?

• C07H 5/04 - Composés contenant des radicaux saccharide dans lesquels les liaisons carbone-oxygène ont été remplacées par le même nombre de liaisons carbone-hétéro-atomes à des atomes d'halogènes, d'azote, de soufre, de sélénium ou de tellure à l'azote
• C07H 7/06 - Radicaux hétérocycliques
• C07F 5/02 - Composés du bore

Abrégé

The present invention relates to peptidic carbaborane-modified Ghrelin receptor agonists for application in boron neutron capture therapy (BNCT).

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61P 35/00 - Agents anticancéreux
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique

Abrégé

4= to a process for preparation thereof and to the use thereof, especially in medicine, for example in the inhibition of lipoxygenase.

Classes IPC  ?

• C07F 5/02 - Composés du bore
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 37/08 - Agents antiallergiques

Abrégé

A method for adapting a matching model of an object comprising the step of providing an electronic image of the object; providing a matching model of the object, the matching model consisting of a plurality of points; determining a pose of the object in said electronic image by using a matching approach that uses said matching model; transforming the matching model according to said pose, yielding a transformed model; determining for at least one point of said transformed model a corresponding point in said electronic image; and adapting the matching model according to the at least one determined corresponding point.

Classes IPC  ?

• G06T 7/73 - Détermination de la position ou de l'orientation des objets ou des caméras utilisant des procédés basés sur les caractéristiques
• G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
• G06T 7/246 - Analyse du mouvement utilisant des procédés basés sur les caractéristiques, p. ex. le suivi des coins ou des segments
• G06K 9/48 - Extraction d'éléments ou de caractéristiques de l'image en codant le contour de la forme
• G06T 3/00 - Transformations géométriques de l'image dans le plan de l'image
• G06K 9/46 - Extraction d'éléments ou de caractéristiques de l'image

Abrégé

The invention relates to a component for electric, magnetic, or optical applications, comprising at least two adjacent layers (GB1, GB2) with a common boundary region (GFB). The first layer has graphite with a Bernal crystal structure (graphite 2H), and the second layer has graphite with a rhombohedral crystal structure (graphite 3R). The boundary region has at least one boundary area (GG) which has superconductive properties at a transition temperature (Tc) higher than 78 K and/or a critical magnetic flux density (Bk) greater than 1 T.

Classes IPC  ?

• H01L 39/12 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails caractérisés par le matériau
• H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
• H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par  ou de leurs parties constitutives
• C01B 32/20 - Graphite

Abrégé

a detector configured to receive an image of the zone in said direction X.

Classes IPC  ?

• G01R 23/163 - Analyse de spectreAnalyse de Fourier adaptées à la mesure dans des circuits comportant des constantes réparties
• G01R 23/17 - Analyse de spectreAnalyse de Fourier avec des dispositifs optiques auxiliaires
• G01R 29/08 - Mesure des caractéristiques du champ électromagnétique
• G01R 33/32 - Systèmes d'excitation ou de détection, p. ex. utilisant des signaux radiofréquence
• G01R 33/60 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance paramagnétique électronique

Abrégé

a), and detecting the Raman scattered radiation (7); registering the Raman scattered radiation of the irradiated blood vessel using the device for introducing the laser light, and for detecting the Raman scattered radiation, wherein, during the measuring process, a movement of the blood vessel out of the focus can be avoided by tracking using the vision system; evaluating the Raman scattered radiation in an evaluation unit; determining and displaying the sex of the embryo in the bird's egg.

Classes IPC  ?

• G01J 3/44 - Spectrométrie RamanSpectrométrie par diffusion
• G01N 21/65 - Diffusion de Raman
• G01N 33/483 - Analyse physique de matériau biologique
• G01N 33/08 - Œufs, p. ex. par mirage

Abrégé

The invention relates to chemical compounds of the general structure [A - R3 - X - R4] where A = [R1 - R2] or [R1] R1 = aryl, heteroaryl R2 = alkyl, aryl, heteroaryl, carbonyl, thiocarbonyl, alkyl ester, alkyl thioester R3 = O, S, NH X = closo- or nido-boron cluster R4 = formula (I) where Z = OH, SH, NH2 where R5 is selected from H, alkyl, aryl, heteroaryl, alkyl ether, alkyl thioether, alkylamine and R6 is selected from alkyl, aryl, heteroaryl, alkyl ether, alkyl thioether, alkylamine and where R3 and R4 are in meta or para positions to one another, to a process for preparation thereof and to the use thereof, especially in medicine, for example in the inhibition of lipoxygenase.

Classes IPC  ?

• C07F 5/02 - Composés du bore
• A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and oncocin, preferably having increased stability, reduced immunoreaction, and improved pharmacokinetics. In the invention, the peptide antibiotics are reversibly protected by means of a linker having the polymer polyethylene glycol (PEG). The peptide linker contains a recognition sequence for trypsin-like serum proteases. In the apidaecin derivatives, the linker and the PEG are bonded to a side chain. In the serum, the linker is cut by serum proteases and PEG is separated off. The released peptide still contains remnants of the linker, which are still bonded to the amino group in the side chain. Astonishingly, said remaining remnants of the linker impair the activity of the antimicrobial peptide only a little or not at all.

Classes IPC  ?

• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A01N 37/46 - Dérivés N-acylés
• A01N 63/02 - Substances produites par, ou obtenues à partir de micro-organismes ou d'animaux
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
• A01N 25/22 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des ingrédients stabilisant les ingrédients actifs
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
• C07K 11/00 - Depsipeptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The invention relates to a peptide, comprising (i) a main chain comprising at least one L-3,4-dihydroxyphenylalanine (DOPA), (ii) at least one integrin-binding peptide, and (iii) at least one heparin-binding peptide. The invention further relates to a coating of metal surfaces, comprising the peptide according to the invention, and a coated metal surface that can be obtained by reacting the peptide according to the invention with a metal surface.

Classes IPC  ?

• A61L 27/28 - Matériaux pour le revêtement de prothèses
• A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• A61K 6/00 - Préparations pour la technique dentaire
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 17/14 - Peptides immobilisés sur, ou dans, un support inorganique
• C07K 5/087 - Tripeptides la chaîne latérale du premier amino-acide contenant des carbocycles, p. ex. Phe, Tyr

Abrégé

The present invention relates to the conception and synthesis of symmetrical cycloalkines and to a method for producing cycloalkines in a 1,3-dipolar cycloaddition of the cycloalkines according to the invention with a 1,3-dipolar compound.

Classes IPC  ?

• C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons

Abrégé

The present invention relates to novel phenylphosphates and naphthylphosphates, to the prodrugs thereof and to the (pharmaceutically) acceptable salts thereof, and to the use thereof as medicaments for the selective inhibition of the STAT5 protein, especially for use in cancer treatment. Advantageously, the novel compounds according to the general formula (I) and (II) inhibit the STAT5 protein by selective and specific interaction, these compounds having an activity at least 50 times higher for the selective inhibition of the STAT5 protein than currently known compounds.

Classes IPC  ?

• C07F 9/141 - Esters des acides phosphoreux

Abrégé

The invention relates to a system (10) for analysis of a microwave frequency signal (HF) by imaging, comprising: - a solid material (M) having at least one optical property that is modifiable in at least one zone (Zo) of said material when said zone is simultaneously in the presence of an optical excitation (Eo) or electrical excitation (Ee) and a microwave frequency signal having at least one frequency coincident with a resonance frequency (fR) of the material, said material also having the property that a value of said resonance frequency (fR(B)) varies as a function of the amplitude of a magnetic field, - a magnetic field generator (GB) configured to generate a magnetic field (B) having, inside a part of said zone, a spatial amplitude variation (B(x)) along a direction X, said material therefore having a resonance frequency (fR(x)) function of a position (x) along said direction X, and - a detector (D) configured to receive an image (Im) of said zone (Zo) along said direction X.

Classes IPC  ?

• G01R 23/17 - Analyse de spectreAnalyse de Fourier avec des dispositifs optiques auxiliaires
• G01R 23/163 - Analyse de spectreAnalyse de Fourier adaptées à la mesure dans des circuits comportant des constantes réparties

Abrégé

The invention relates to a method for the Raman spectroscopic, in ovo sex determination of fertilised and incubated birds' eggs (1), wherein the embryo, including the extra-embryonic structures, can move in the egg, and is not yet attached to the shell at the time of measuring. In addition, the following steps are carried out: monitoring the time course of the incubated egg until at least one recognisable blood vessel (21) is formed; creating a hole (2) in the shell in the region near to the attached blood vessel, using a hole-generating unit; finding the blood vessel forming in the egg using a vision system (19, 13) and a coaxial or lateral illumination with light (10a) in the visible wavelength range; positioning at least one blood vessel in the laser focus of a laser source (3), either by moving the egg or moving a lens (6) of a device (5) for introducing the laser light (3a), and detecting the Raman scattered radiation (7); registering the Raman scattered radiation of the irradiated blood vessel using the device for introducing the laser light, and for detecting the Raman scattered radiation, wherein, during the measuring process, a movement of the blood vessel out of the focus can be avoided by tracking using the vision system; evaluating the Raman scattered radiation in an evaluation unit; determining and displaying the sex of the embryo in the bird's egg.

Classes IPC  ?

• G01N 21/65 - Diffusion de Raman
• G01N 33/08 - Œufs, p. ex. par mirage

Abrégé

The present invention relates to a novel soluble biomarker for insulin resistance: 1-methyl nicotinamide (MNA). The invention relates to methods of determining the degree of insulin resistance in a patient. The invention further relates to methods for determining whether a subject with insulin resistance or type 2 diabetes will benefit from a treatment with an inhibitor of nicotinamide-N-methyltransferase (NNMT) or whether a subject responds to a therapeutic treatment with an NNMT inhibitor. The invention also relates to methods of adjusting the dose of an NNMT inhibitor applied for therapeutic treatment of insulin resistance or type-2 diabetes

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Staphylococcus aureus. According to the invention, the object is attained in a first aspect by a peptide according to claim 1.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides

Abrégé

The invention relates to a mitochondrial expression vector which may comprise a gene to be expressed and/or a selection marker and a mitochondrial region, and a method for inserting a DNA to be expressed into mitochondria of mammalian cells, wherein the method may comprise the steps: (i) construction of a mitochondrial expression vector or a mitochondrial genome, (ii) reversible induction of megamitochondria and (iii) transfection of the megamitochondria by means of a physical transfection method.

Classes IPC  ?

• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The invention provides a device for a medical treatment of a sclera, the device comprising a single applicator connected to a shaft, wherein the applicator is configured to be placed into the Tenon's space; the applicator has a first surface, wherein the first surface of the applicator is superficially contactable to the surface of an area of the sclera so as to superficially cover said area; and the applicator comprises a single optical outlet connected to a single optical guiding element extending from a proximal end of the shaft to the single distal optical outlet at the first surface of the applicator, the optical guiding element being configured for guiding electromagnetic waves towards the optical outlet, wherein the optical guiding element is configured to guide electromagnetic waves of a wavelength adapted for thermal treatment of the sclera by protein coagulation.

Classes IPC  ?

• A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
• A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil

Abrégé

The present invention relates to highly potent ligands at the ghrelin receptor to influence food intake or other conditions.

Classes IPC  ?

• C07K 7/22 - ElédoïsinesPeptides apparentés

Abrégé

The invention relates to a method and means for the non-invasive diagnosis of type II diabetes mellitus The glycation state is determined in at least one glycation position of selected plasma proteins.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relatesto a polypeptideconsisting of or comprising a variant of human trypsinogen-1, comprising the substitutions: amino acid residue E64 is replaced with an amino acid residue comprising a positively charged side chain, amino acid residue K123 is replaced with an amino acid residue comprisingan aliphatic side chain and amino acid residues Y139 and D147 are replaced with a glutamine or asparagine residue, and wherein said variant is further characterized in that: an amino acid residue selected from E16, E17 and E142 is replaced with an amino acid residue comprising an aliphatic side chain, and/or amino acid residue N18 is replaced with a histidine residue, and/or amino acid residue R107 is replaced with a lysine residue, and/or amino acid residue D138 is replaced with an amino acid residue comprising a positively charged side chain, and wherein said variant is cleavable into a polypeptide having a native-like enzymatic activity when compared to human trypsin-1.

Classes IPC  ?

• C12N 9/76 - TrypsineChymotrypsine
• C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
• G01N 33/542 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec inhibition stérique ou modification du signal, p. ex. extinction de fluorescence
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées

Abrégé

The invention relates to a hydrophobed porous oil binder in the form of a nonwoven fabric composed of lignocellulose-containing raw materials having a biologically functionalized surface for removing mineral-oil-based contaminants in seas, rivers, inland waters, and stormwater basins or wastewater treatment plants, wherein the density of the oil binder is 10 to 900 kg/m3, the oil binder is 1 to 25 mm thick, the broad surface of the oil binder has a dimension of 9 to 200 cm2, the porosity of the oil binder is 30 to 96%, measured with respect to the total fraction of the oil binder, and the flexural strength of the oil binder is at least 1.5 N/mm2.

Classes IPC  ?

• B01J 20/24 - Composés macromoléculaires d'origine naturelle, p. ex. acides humiques ou leurs dérivés
• B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
• C09K 3/32 - Substances non couvertes ailleurs pour traiter les polluants liquides, p. ex. le pétrole, l'essence ou les corps gras
• C02F 1/68 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par addition de substances spécifiées, pour améliorer l'eau potable, p. ex. par addition d'oligo-éléments
• D04H 1/00 - Non-tissés formés uniquement ou principalement de fibres coupées ou autres fibres similaires relativement courtes
• E02B 15/10 - Dispositifs pour enlever les substances de la surface

Abrégé

The present invention relates to a method for determining an amount of a peroxide in a sample, wherein the method comprises the steps of: - providing a sample, - contacting the sample with a terbium(III) benzene dicarboxylic acid complex, and - determining the luminescence of the terbium(III) benzene dicarboxylic acid complex.

Classes IPC  ?

• C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une oxydoréductase
• C12Q 1/54 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir le glucose ou le galactose
• C12Q 1/60 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir le cholestérol

Abrégé

The present invention relates to a device and a method for parallel recording of impedance spectra and field potential of cells in vitro.

Classes IPC  ?

• G01N 27/327 - Électrodes biochimiques
• G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
• G01N 33/483 - Analyse physique de matériau biologique

Abrégé

The present invention relates to the therapeutic use of activators of the zinc finger protein GLI3 in diseases that are associated with reduced Hedgehog signaling in hepatocytes, in particular Polycystic ovary syndrome, Steatosis hepatis, Steatohepatitis and/or Adipositas. The invention further relates to methods of treating an individual with said activator, a pharmaceutical composition comprising said activator and the use of said activator as food supplement.

Classes IPC  ?

• A61K 38/22 - Hormones
• A61K 31/4436 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle
• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07K 14/575 - Hormones

Abrégé

The invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and oncocin, preferably having increased stability, reduced immunoreaction, and improved pharmacokinetics. In the invention, the peptide antibiotics are reversibly protected by means of a linker having the polymer polyethylene glycol (PEG). The peptide linker contains a recognition sequence for trypsin-like serum proteases. In the apidaecin derivatives, the linker and the PEG are bonded to a side chain. In the serum, the linker is cut by serum proteases and PEG is separated off. The released peptide still contains remnants of the linker, which are still bonded to the amino group in the side chain. Astonishingly, said remaining remnants of the linker impair the activity of the antimicrobial peptide only a little or not at all.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
• A01N 37/46 - Dérivés N-acylés
• A01N 63/02 - Substances produites par, ou obtenues à partir de micro-organismes ou d'animaux
• C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
• A01N 25/22 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des ingrédients stabilisant les ingrédients actifs
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The invention relates to a method for decellularising organs or tissues in a reactor, the reactor comprising: one or more tubular nozzle(s) wherein: the tubular nozzle(s) are mounted in the interior of the reactor; and fluid can be fed into the tubular nozzle(s) from outside the reactor through an inlet; an outlet; wherein each of the organs or tissues to be decellularised is positioned in the interior of the reactor; wherein a cleaning solution is present in the reactor; and wherein the method comprises the following steps: (1a) pressing a cleaning solution under pressure through the respective inlets into the tubular nozzles; (1b) suction of cleaning fluid from the reactor through the outlet; wherein the pressure in step (1a) is selected such that in the reactor strong laminar and/or turbulent flows and eddies occur in the cleaning solution. Some embodiments of the invention additionally permit an effective removal of matrix-bound cleaning solution.

Classes IPC  ?

• C12M 1/26 - Inoculateur ou échantillonneur
• C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels

Abrégé

The invention relates to a method for the prognostic estimation of the course of the disease in rheumatoid arthritis, especially the prognostic estimation of the course of the disease under therapy, and also for diagnosis and/or determination activity of the rheumatoid arthritis via the analysis of cytokines from a human whole blood sample. According to the method according to the invention, a volume of a whole blood sample from a human is transferred into at least one tube containing a stimulating agent. As comparative samples, in each case, the same volume of a whole blood sample from the human is transferred in each case into an empty tube as a negative control and a tube containing lipopolysaccharide as a positive control. After incubation, from the cell-free supernatant of the respective tube, the concentration of at least one pro-inflammatory cytokine is determined. On the basis of a changed concentration of the at least one cytokine in the at least one tube containing the stimulating agent, then the prognostic estimation of the course of the disease and the diagnosis is made. In addition, the invention relates to an associated diagnostic kit and use thereof. The invention is used in medical diagnosis and medical research.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

The present application relates to a single stranded nucleic acid hybridizing to a splicing motif of an exon in a mRNA of a stimulating T-cell receptor or co-receptor, and wherein said exon codes for a transmembrane domain. Furthermore, the present application relates to methods of treating a transplant as well as to single stranded nucleic acids for use as a medicament, preferably for use in the treatment of graft versus host disease.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

Disclosed herein are methods for identifying an agent for treating or preventing neurogenerative disease and to methods for recapitulating tauopathies using a tau protein that includes at least four different mutations that cause the condition frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and to nucleic acids encoding the tau protein.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The present invention relates to a method for preparation of a 2-chloro-1,10- phenanthrolinamine, comprising the steps: i) conversion of a 2-chloro-1,10-phenanthroline to a 2-chloro-nitro-1,10-phenanthroline characterized by a formula 2, j) hydrogenation of said 2-chloro-nitro-1,10-phenanthroline characterized by formula 5 to a 2-chloro-1,10-phenanthrolinaminecharacterized by formula 3. The present invention relates further to a method for preparationofa2-[2-[bis(carboxymethyl)amino]ethyl-[2-[carboxymethyl-[2-[4-[2-(isothiocyanato-1,10-phenanthrolin-2-yl)ethynyl]anilino]-2-oxo-ethyl]amino]ethyl]amino]acetic acidcharacterized by formula 7 and a method for quantifying a biomolecule in a sample.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a device for a medical treatment of a sclera, the device (100) comprising a curved disc or a belt (102), wherein the disc/belt is configured to be placed into the Tenon's space; the disc/belt is formed such that the inner surface of the curved disc/belt is superficially contactable to the surface of an area of the sclera so as to superficially cover said area; and the disc/belt comprises one, two, three, four, or more independent channel systems (101).

Classes IPC  ?

• A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main

Abrégé

The invention relates to a mitochondrial expression vector comprising a gene to be expressed and/or a selection marker and a mitochondrial promoter region, and a method for inserting a DNA to be expressed into mitochondria of mammalian cells, wherein the method comprises the steps: (i) construction of a mitochondrial expression vector or a mitochondrial genome, (ii) reversible induction of megamitochondria and (iii) transfection of the megamitochondria by means of a physical transfection method.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The present invention relates to the development of a new live fowl typhoid (FT) vaccine candidate against Salmonella Gallinarum (SG), with two independent attenuating mutations based on metabolic drift (MD), spontaneous chromosomal mutations. Such vaccine candidate fulfills the security demand of the World Health Organization (WHO). The vaccine proved to be genetically stable, safe and effective in experimental studies. This attenuated vaccine strain is designed sufficiently invasive to induce immunity in poultry, in particular chickens, and the vaccinated animals were protected against experimental SG challenge. The vaccine can be used for chicken and can be administered orally which is an easy and cost effective alternative to injection.

Classes IPC  ?

• C12R 1/42 - Salmonella
• A61K 39/02 - Antigènes bactériens

Abrégé

The invention relates to a method and a device for characterising cells in terms of the temperature dependency of the mechanical properties thereof. Due to the partial decoupling of mechanical deformation and heating in the method, the temperature dependency of the mechanical properties has become experimentally accessible for the first time. According to the invention, deformation occurs by means of a microrheological device, and heating takes place locally at the cell by at least one heating laser with a beam course distanced from the sample.

Classes IPC  ?

• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
• G01N 15/10 - Recherche de particules individuelles

Abrégé

The present invention relates to the therapeutic use of activators of the zinc finger protein GLI3 in diseases that are associated with reduced Hedgehog signaling in hepatocytes, in particular Polycystic ovary syndrome,Steatosis hepatis, Steatohepatitis and/or Adipositas. The invention further relates to methods of treating an individual with said activator, a pharmaceutical composition comprising said activator and the use of said activator as food supplement.

Classes IPC  ?

• A61K 38/22 - Hormones
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées

Abrégé

The subject matter of the present invention relates to a method and a device for determining properties of objects with sizes in the micrometre or nanometre range. The objects are themselves magnetisable or are connected to magnetisable particles. According to the invention, the objects are introduced into a homogeneous magnetic field from two or three orthogonally arranged Helmholtz coils (2, 3). Local microscopic disturbances are produced in the homogeneous magnetic field by a magnetisable local disruption structure, such as the magnetisable particles themselves. Properties of the objects can be inferred from the reaction of the objects to these disturbances or to variations of the field strength and/or field direction of one or more of the Helmholtz coils.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The present invention relates to a method for generating melanocytes from stem cells comprising the steps of: (i) removing the bulb of an epilated human hair; (ii) incubating the remaining part of the epilated hair with a collagen degrading agent to separate stem cells from the outer root sheath; (iii) cultivating the separated stem cells from step (ii) in a medium that induces differentiation and stimulates growth of stem cells, melanocyte precursors and melanocytes, wherein the medium comprises one or more growth factors for differentiation into melanotic melanocytes. Furthermore, a method for producing an autograft, a homograft or an allograft comprising melanocytes is disclosed herein as well as autografts, a homografts and allografts or melanocytes for the treatment of diseases related to depigmentation of the skin or for the treatment of scars.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
• A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées

Abrégé

The present invention relates to a device and a method for parallel recording of impedance spectra and field potential of cells in vitro.

Classes IPC  ?

• G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
• G01N 33/483 - Analyse physique de matériau biologique

Abrégé

The present invention relates to highly potent ligands at the ghrelin receptor to influence food intake or other conditions.

Classes IPC  ?

• C07K 7/22 - ElédoïsinesPeptides apparentés
• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés

Abrégé

The present invention relates to bicyclic labdane diterpenes for use in the treatment of a disease associated with activation of transient receptor potential cation channel 6 (TRPC6), preferably a pulmonary or a renal disease. In one aspect the invention relates to the use of a bicyclic labdane diterpene for blocking calcium transport via TRPC6. Another aspect of the invention is a bicyclic labdane diterpene according to formula (1) for use as a medicament wherein R1 is selected from hydrogen and C1 to C4 acyl, wherein the bicyclic labdane diterpene optionally comprises at least one double bond between the carbon atoms at positions 1 and 2, 2 and 3, 5 and 6, 6 and 7 and/or 14 and 15, wherein the carbon atoms at positions 1, 2, 3, 7, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 are connected to hydrogen atoms or comprise at least one substitution.

Classes IPC  ?

• A61K 31/35 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The invention relates to a compound of formula Ia or Ib wherein R1 represents -CO2R3, -COR4or -R5, wherein R3 represents unsubstituted or substituted C1-C6 alkyl, R4 represents hydrogen, unsubstituted or substituted C1-C6 alkyl, and R5 represents hydrogen, unsubstituted or substituted C1-C6 alkyl, R2 represents -N+ (R6)(R7)(R8)X- or a nitro group, wherein R6, R7, R8 independently of each other represent unsubstituted or substituted C1-C6 alkyl or unsubstituted or substituted -(CH2)n- with n = 1 to 12 provided that at least two of the substituents R6 R7 R8 are C1-C6 alkyl, and X- represents a halide, sulphonate, unsubstituted or substituted acetate, sulphate, hydrogen sulphate, nitrate, perchlorate, or oxalate.

Classes IPC  ?

• C07D 451/02 - Composés hétérocycliques contenant des systèmes cycliques aza-8 bicyclo [3.2.1] octane, aza-9 bicyclo [3.3.1] nonane ou oxa-3 aza-9 tricyclo [3.3.1.02,4] nonane, p. ex. alcaloïdes du tropane ou du granatane, scopolamineLeurs acétals cycliques contenant des systèmes cycliques aza-8 bicyclo [3.2.1] octane ou oxa-3 aza-9 tricyclo [3.3.1.02,4] nonane sans autre condensation, p. ex. tropaneLeurs acétals cycliques

Abrégé

The invention relates to a method and a device for twin-focus photothermal correlation spectroscopy for the characterization of dynamical processes in liquids and biomaterials with the help of absorbing markers. Thereby non-fluorescent absorbing nano objects are heated by an intensity-modulated heating laser which leads to a refractive index gradient lens around the object. This refractive index gradient is detected by a detection laser with a focal volume that, depending on the position of the heated object relative to the focal plane of the detection beam, splits into two-sub-volumes forming a twin-focus comprising two sharply separated parts of a focal volume showing no spatial overlap.

Classes IPC  ?

• G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné

Abrégé

The invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and oncocin, preferably having increased stability, reduced immunoreaction, and improved pharmacokinetics. In the invention, the peptide antibiotics are reversibly protected by means of a linker having the polymer polyethylene glycol (PEG). The peptide linker contains a recognition sequence for trypsin-like serum proteases. In the apidaecin derivatives, the linker and the PEG are bonded to a side chain. In the serum, the linker is cut by serum proteases and PEG is separated off. The released peptide still contains remnants of the linker, which are still bonded to the amino group in the side chain. Astonishingly, said remaining remnants of the linker impair the activity of the antimicrobial peptide only a little or not at all.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
• A01N 37/46 - Dérivés N-acylés
• A01N 63/02 - Substances produites par, ou obtenues à partir de micro-organismes ou d'animaux
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The invention relates to a method for producing self-supporting titanium oxide- and/or vanadium oxide-based porous materials, in particular to a method for producing titanium oxide and/or vanadium oxide particles, preferably by means of template synthesis, to the porous materials which can be obtained in this manner, and to the use thereof.

Classes IPC  ?

• B01J 21/06 - Silicium, titane, zirconium ou hafniumLeurs oxydes ou hydroxydes
• B01J 23/22 - Vanadium
• B01J 37/00 - Procédés de préparation des catalyseurs, en généralProcédés d'activation des catalyseurs, en général
• C01G 23/04 - OxydesHydroxydes
• C01G 31/02 - Oxydes

Abrégé

The invention relates to a method and a device (1, 100) for determining the sex of fertilized, nonincubated bird eggs (13, 130), where an egg (13, 130) has a solid egg shell (14), an egg yolk (2) which is surrounded by the egg shell and further egg integuments and a blastodisc (3) associated with the egg yolk (2), and where a probe (4, 40) for measuring a spectrum is introduced through a hole (17) of the egg shell (14) towards the blastodisc (3) with blastodisc cells (23), with the following steps: —positioning of the probe (4, 40) in the region of the blastodisc (3), —spectroscopic in-ovo characterization of the blastodisc cells (23), and —identification of the sex by an automatic classification of spectra.

Classes IPC  ?

• G01J 5/02 - Détails structurels

Abrégé

The invention relates to a method for producing self-supporting mixed metal oxide-based porous materials, in particular to a method for producing mixed oxide particles of at least two different metals, preferably by means of template synthesis, to the porous materials which can be obtained in this manner, and to the use thereof.

Classes IPC  ?

• B01J 37/00 - Procédés de préparation des catalyseurs, en généralProcédés d'activation des catalyseurs, en général
• B01J 21/06 - Silicium, titane, zirconium ou hafniumLeurs oxydes ou hydroxydes
• B01J 23/22 - Vanadium
• B01J 23/00 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe
• B01J 23/10 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe des terres rares
• B01J 21/12 - Silice et alumine
• B01J 23/889 - Manganèse, technétium ou rhénium
• B01J 23/31 - Chrome, molybdène ou tungstène combinés au bismuth

Abrégé

The present invention relates to a tau protein comprising at least four different mutations selected from group consisting of mutations which cause the condition frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and to nucleic acids encoding said tau protein. The invention further pertains to methods for identifying an agent for treating or preventing neurogenerative disease, and to methods for recapitulating tauopathies.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The invention concerns a method and means for distinguishing malignant from benign tumor samples of the thyroid, by performing a RNA extraction in a standard fine needle aspiration biopsy (FNAB) sample, in particular an air dried FNAB smear. The presence of gene- rearrangements and/or the expression of miRNA is analyzed in the isolated RNA, wherein the presence of a gene-rearrangement and/or the differential expression of miRNA is indicative for a malignant tumor.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to novel quinazoline derivatives which are suitable as diagnostic and therapeutic drugs and can be used especially for diagnosis and treatment of neurodegenerative and psychiatric disorders, for example schizophrenia. The novel quinazoline derivatives are notable for a high affinity and selectivity for PDE10A and by virtue of having at least one halogen-substituted substituent on the quinazoline radical.

Classes IPC  ?

• C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie

Abrégé

A method for diagnosis and/or prognosis of cancers, for diagnosis of the site of origin of tumour cells, for optimizing the treatment of cancer patients and for screening active substances for oncology. In the method, the mechanical properties of tumour cells and reference cells are analyzed under a mechanical load that leads to linear or nonlinear deformation of the respective loaded cell. The expansion of the cells, which results from the input of a directed mechanical stress, is used to determine the risk of tumour metastases and, if appropriate, the presence of uncontrollably proliferating and/or invasive cells, or the tissue of origin of the tumour. The risk of tumour metastases is determined on the basis of the proportion of cells in the sample that have an extension counter to the direction of stressing. The risk of the presence of uncontrollably proliferating cells is determined, in the case of nonlinear deformation of the cell, on the basis of the mean value of the expansion in the direction of stressing of cells in the sample.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The invention relates to a method for producing methane by culturing algae and methanogenic microorganisms, and to a facility for carrying out the process. The essence of the invention is a photobioreactor which directly generates methane from two zones composed of sunlight and an oxygen-enriched and carbon-dioxide-depleted gas mixture. The reaction is carried out in two sub steps which take place in two different zones. In the first, aerobic part, glycolate is synthesized in algal cells by photosynthesis, and this glycolate is excreted by the cells. The algae form a biofilm on a support material, which biofilm is firstly supplied by nutrients with the aid of a continuous or semicontinuous stream of liquid and secondly transfers the excreted glycolate into the second zone. This compartment is anaerobic due to an oxygen-impermeable membrane and comprises methanogenic bacteria, which directly convert the introduced glycolate into methane.

Classes IPC  ?

• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/113 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens pour recueillir les gaz de fermentation, p. ex. le méthane avec transport du substrat pendant la fermentation
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• C12M 1/18 - Compartiments ou champs multiples
• C12P 5/02 - Préparation des hydrocarbures acycliques
• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12R 1/89 - Algues

Abrégé

The present invention is based on two important experimental observations: The first observation is that increased extracellular concentrations of ionized calcium are found in erosive arthritis and stimulate monocytic IL-1ß release via the CaSR and GPRC6A. Simultaneous stimulation of monocytes with calcium ions and selected TLR ligands results in a 20-fold increased IL1ß response compared to lipopolysaccharide (LPS) alone. During the crosstalk between GPCR and TLR signaling, phospholipase C is activated, which triggers calcium dependent potassium channels, resulting in potassium efflux, caspase-1 activation and IL-1ß release. The amplification of IL1ß secretion at sites of locally increased calcium ion concentrations aggravates rheumatoid arthritis. The second important observation is that both CaSR and GPRC6A, are highly expressed in the synovial membrane of patients with rheumatoid arthritis, but expression of GPRC6A, but not of CaSR, is lower in patients with osteoarthritis (s. Fig 1). The latter is generally not accompanied by inflammation. Thus, expression of GPRC6A appears to be upregulated in chronic inflammatory situations. Based on these experimental observations the invention provides a method and compositions for the identification of agents that have a potential effect against chronic inflammatory conditions, in particular erosive arthritis and atherosclerosis.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to an in vitro method for diagnosing and/or monitoring in a subject a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor, comprising detecting and/or analyzing in a test sample derived from the subject one or more mutations at the DNA level in any one or both of the marker genes cKIT (GenBank acc. no. NM_000222.2) and PDGFRA (GenBank acc.no. NM_006206.4), wherein the DNA is circulating DNA, and wherein the presence of any one of the mutations detected in the test sample is indicative of a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor in the subject. The present invention is also directed to a corresponding kit-of-parts for diagnosing and/or monitoring a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor, comprising means for detecting and/or analyzing one or more mutations as defined herein, as well as to the use of one or more mutations as defined herein as a panel of molecular markers for diagnosing and/or monitoring a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to a antimicrobial peptide or peptide derivative comprising the following sequence: Sub1-X1-D2-K3-P4-P5-Y6-L7-P8-R9-P10-X2-P12-P13-R14-X3-T16-P17-N18-N19-X4-Sub2. The invention further relates to multimers comprising said peptides or peptide derivatives. Moreover, the invention provides a peptide or peptide derivative for use in the treatment of a disease. The peptide or peptide derivative may also be used in the screening for novel antimicrobial compounds.

Classes IPC  ?

• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci

Abrégé

The present invention is directed to a method of producing a soluble recombinant protein by in vitro folding. The present invention is further directed to a recombinant protein, obtainable by this method as well as to a pharmaceutical composition comprising recombinant adiponectin or adiponectin-like protein for use in the treatment of obesity-related metabolic disorders.

Classes IPC  ?

• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Abrégé

The invention relates to an integrated cultivation and measurement device for label-free detection and classification of cellular alterations, in particular for generation and characterisation of cell-spheroids and monitoring the condition of the cell-spheroids in real time, comprising a) a mounting device for a cultivation chamber plate, b) an amplifier board linked with the contacts for the microelectrodes in the mounting device, c) a rotary shaker, on which the amplifier board and the mounting device for the cultivation chamber plate are placed, and d) a control unit, that is linked with the amplifier board and the rotary shaker, wherein the control unit allows recording, analyzing of data and controlling of the movement of the rotary shaker. The cultivation chamber plate has several culture reservoirs, wherein the bottom of each culture reservoir forms a microcavity and each microcavity features microelectrodes on the microcavity walls. The mounting device has contacts for the microelectrodes. The invention advantageously allows the automated generation, cultivation and characterisation of spheroids, as well as the cultivation and characterisation of tissue probes.

Classes IPC  ?

• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• G01N 27/02 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance
• G01N 27/26 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant des variables électrochimiquesRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en utilisant l'électrolyse ou l'électrophorèse
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables

Abrégé

The invention relates to a method and a device (1, 100) for determining the sex of fertilized, nonincubated bird eggs (13, 130), where an egg (13, 130) has a solid egg shell (14), an egg yolk (2) which is surrounded by the egg shell and further egg integuments and a blastodisk(3) associated with the egg yolk (2), and where a probe (4, 40) for measuring a spectrum is introduced through a hole (17) of the egg shell (14) towards the blastodisk (3) with blastodisk cells (23), with the following steps: - positioning of the probe (4, 40) in the region of the blastodisk (3), - spectroscopic in-ovo characterization of the blastodisk cells (23), and - identification of the sex by an automatic classification of spectra. The problem is that of rapidly, reliably and unambiguously determining the sex as early as during the bird egg stage. The solution is as follows: an optical crystal is employed as the probe (4, 40), by means of which optical crystal a rapid and retroaction-free recording of an infrared and/or near-infrared spectrum (70) is carried out by exploiting a reduced total reflection (31) within the optical crystal (4, 40) through an evanescent field (21) within the region (29) of the blastodisk (3), with extinction taking place as a result of a spectral absorption of sex-specific blastodisk cells (23), where the positioning of the optical crystal (4, 40) is accompanied by an ongoing automatic evaluation of the returned spectra (70) until the sex-specific blastodisk cells (23) are determined, until the sex of the fertilized egg (13, 130) is evaluated by an evaluation unit (7) and unambiguously displayed by a display unit (12).

Classes IPC  ?

• G01N 21/35 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge
• G01N 21/55 - Réflexion spéculaire
• G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones

Abrégé

The present invention provides a pharmaceutical composition comprising an LRP1 receptor agonist for use in the treatment of cancer characterized by an up-regulated or constitutiveIy active Wnt signaling pathway and a method for identifying LRP1 receptor agonists suitable as therapeutic agents for treating such cancers. The present invention also provides a pharmaceutical composition comprising an LRP1 receptor agonist for use in the treatment of an HIV-infection. Furthermore, the present invention relates to the therapeutic use of LRP1 receptor agonists and a kit of parts comprising the pharmaceutical composition according to the invention.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 35/00 - Agents anticancéreux
• A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV

Abrégé

The present invention refers to a novel circovirus as causative agent of bone marrow aplasia with haemorrhagic disease in cattle. The present invention provides novel nucleic acid and protein sequences for diagnostic and therapeutic uses.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• C07K 14/01 - Virus à ADN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

The invention relates to transparent rectifying contact structures for application in electronic devices, in particular appertaining to optoelectronics, solar technology and sensor technology, and also a method for the production thereof. The transparent rectifying contact structure according to the invention has the following constituents: a) a transparent semiconductor, b) a transparent, non-insulating and non-conducting layer composed of metal oxide, metal sulphide and/or metal nitride, the resistivity of which is preferably in the range of 102 Ωcm to 107 Ωcm and c) a layer composed of a transparent electrical conductor wherein the layer b) is formed between the semiconductor a) and the layer c) and the composition of the layer b) is defined in greater detail in the description of the patent.

Classes IPC  ?

• H01L 31/108 - Dispositifs sensibles au rayonnement infrarouge, visible ou ultraviolet caractérisés par une seule barrière de potentiel ou de surface la barrière de potentiel étant du type Schottky
• H01L 31/18 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives

Abrégé

The present invention finds application in the field of medicine and, in particular, to new compounds particularly active in inhibiting Rac1 member of the Rho family. Pharmaceutical preparations containing them useful for the treatment and/or prevention of heart failure are disclosed as well.

Classes IPC  ?

• C07D 239/47 - Un atome d'azote et un atome d'oxygène ou de soufre, p. ex. cytosine
• C07D 239/48 - Deux atomes d'azote
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque

Abrégé

A process for the preparation of large-ring cyclodextrins (LR-CD) with a degree of polymerisation (DP) of 9 - 21 from starch is described. LR-CD are obtained in a biocatalytic process in high yields by controlling the temperature and reaction time. The LR-CD mixtures obtained are separated from glucose and others reaction products in a precipitation process. After removal of smaller CD by complexation reactions enhanced by an ultrasonication treatment, CD9 to CD21 can then be obtained in high purity following separation by preparative liquid chromatography on a combination of reversed (ODS, octadecyl silicate) and amino phases. Smaller CD, in particular CD6, CD7 and CD8, (α-, β-, and Ƴ-cyclodextrin) and their derivatives are already produced commercially in large scale. In contrast, owing to the low yields in previously described production processes and the difficulties in their isolation, it has been not possible to obtain LR-CD in any larger amounts. The invention allows the preparation of single LR-CD in pure form obtained in high yields in a biocatalytic process.

Classes IPC  ?

• C08B 37/16 - CyclodextrineSes dérivés
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament

Abrégé

Described are vectors containing (a) a gene encoding (i) a CDK4/CDK6 inhibitor, preferably p16INK4a, or (ii) an RNA interfering with CDK4 and/or CDK6 expression and/or activity, under the control of an inducible promoter and (b) a gene encoding a transactivator protein for said promoter useful for treating neurodegenerative disorders. These vectors can be transferred into cells where they will exert a protective function to (i) prevent cell death or to (ii) slow down progression of cell death. These vectors can be used in therapeutic applications to prevent neurodegenerative disorders or to slow down their progression with therapeutic efficacy.

Classes IPC  ?

• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance

Abrégé

The present invention relates to novel compounds of formula (I) that inhibit cell proliferation, in particular by inhibiting selectively Aurora A kinase activity and to their use in medicine, in particular for treating, ameliorating or preventing hyperproliferative diseases. The invention further relate to methods of their preparation, pharmaceutical compositions including such compounds.

Classes IPC  ?

• C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
• A61P 35/00 - Agents anticancéreux

Abrégé

Basic steps of biological research and of diagnostics include mixing, physical and/or chemical reactions and separation. Particularly in research task-specific laboratory systems are required which are not commercially available due to small batch sizes and the specific problems to be faced. Because of the lack of such systems, researchers and diagnosticians have to improvise with already existing vessels, filters, centrifuges etc. to solve the problems. The aim of the invention is to devise a system of functional units which can be put together depending on the methodological type of problem. The system of functional units which can be freely combined consists of mixing cylinders (2), separation devices (3) and a flow-regulating connecting unit (5) which is preferably a vacuum unit and which is designed to be preferably interconnected in any order with any number of functional units via simple plug-in connections to give a self-contained sample processing system.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• B01L 99/00 - Matière non prévue dans les autres groupes de la présente sous-classe

Abrégé

The invention relates to a method and means for activating memory B lymphocytes, in particular for use in immunological research and in medicine. For the inventive method, the cells are treated with an activating reagent containing pokeweed mitogen, CpG oligonucleotides, IL-2 and IL-10. It is surprising that IL-2, IL-10 and CpG oligonucleotides enhance the activating effect of pokeweed mitogen. The inventors have found that the addition of IL-6, LPS, CD40 ligand or anti-CD40 antibodies, does not have a further activating effect on memory B lymphocytes. This is surprising, because IL-6 is a growth factor for B lymphocytes. According to the invention, therefore, IL-6, lipopolysaccharide of Escherichia coli (LPS), interleukin 6 (IL-6), CD40 ligand and anti-CD40 antibodies are not contained in the activation reagent.

Classes IPC  ?

• A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/20 - Interleukines

Abrégé

The present invention relates to an in-vitro method for the formation of megamitochondria in cells, wherein the cells are grown in a suitable fermentation medium acidulated with lactic acid to pH values between 5.3 and 6.7. The invention further concerns H+ ionophores, ionophores which catalyze the electroneutral exchange of K+ for H+ and inhibitors of actin polymerisation for the prevention or treatment of a disease in which inhibiting or reducing the formation of megamitochondria has a beneficial effect.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C07H 19/00 - Composés contenant un hétérocycle partageant un hétéro-atome du cycle avec un radical saccharideNucléosidesMononucléotidesLeurs anhydro-dérivés

Abrégé

The invention concerns a method and kit for the ex vivo evaluation of the response of a tumor to conditions to be tested, in particular a tumor treatment regime, in an isolated tumor sample. The diagnostic method is suitable for the use in medicine and in pharmacy, in particular for the pretherapeutical evaluation of the responsiveness of a tumor to a tumor treatment regime and the preclinical evaluation of a tumor treatment regime. The method comprises: a.) Placing a freshly isolated tumor sample in a container, which contains antibiotics and preferably antimycotics keeping the sample at a temperature above 10 °C, b.) Breaking up, preferably mechanically disintegrating, the tumor sample, c.) Placing the pieces of the tumor sample into cell culture medium and incubating with collagenase shortly upon isolation of the tumor, d.) Plating the cells and tissue pieces into wells that are coated with extra cellular matrix components, incubating under the conditions of the tumor treatment regime or in presence of a substance to be tested, e.) Determining the number of cells and/or the number of colonies and/or the sum response of cells of epithelial origin, preferably by performing a cytokeratin staining, f.) Using a cell culture medium in the steps c.) to e.) that contains less than 100 nmol/1 flavin and that does not contain phenol red, g.) Performing the steps c.) to e.) in the absence of light of a wavelength below 520 nm.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique